Meta-Analysis of MMP2, MMP3, and MMP9 Promoter Polymorphisms and Head and Neck Cancer Risk

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Zhang, Caiyun ^a   Li, Chao ^b   Zhu, Minhui ^a   Zhang, Qingzhou ^a   Xie, Zhenghua ^a   Niu, Gang ^a   Song, Xicheng ^c   Jin, Lei ^d   Li, Guojun ^e   Zheng, Hongliang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SICHUAN CANCER HOSPITAL   (China)

^c YANTAI YUHUANGDING HOSPITAL   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; STROMELYSIN;

ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; ETHNICITY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HUMAN; LARYNX CANCER; MMP2 GENE; MMP3 GENE; MMP9 GENE; MOUTH CANCER; NASOPHARYNX CANCER; PHARYNX CANCER;

ALLELES; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PUBLICATION BIAS; RISK;

EID: 84876538014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062023     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Siegel R, Naishadham D, Jemal A, (2012) Cancer Statistics. CA Cancer J Clin 62: 10-29.
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK, (1993) Head and neck cancer. N Engl J Med 328: 184-194.
4. Sankaranarayanan R, Nair MK, Mathe WB, Balaram P, Sebastian P, et al. (1992) Recent results of oral cancer research in Kerala, India. Head Neck 14: 107-112.
5. Kabat GC, Chang CJ, Wynder EL, (1994) The role of tobacco,alcohol use, and body mass index in oral and pharyngeal cancer. Int J Epidemiol 23: 1137-1144.
6. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, et al. (1998) Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 48: 3282-3287.
7. Sturgis EM, Wei Q, (2002) Genetic susceptibility-molecular epidemiology of head and neck cancer. Curr Opin Oncol 14: 310-317.
8. Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, et al. (2010) Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res16: 2022-2035.
9. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, et al. (2003) Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 532: 91-107.
10. Stetler-Stevenson WG, Yu AE, (2001) Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 11: 143-52.
11. Nagase H, Woessner JF, (1999) Matrix metalloproteinases. J Biol Chem 274: 21491-21494.
12. Stetler-Stevenson WG, Liotta LA, Kleiner DE, (1993) Extra cellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. Faseb J 7: 1434-1441.
13. Bellayr IH, Mu X, Li Y, (2009) Biochemical insights into the role of matrix metalloproteinases in regeneration: challenges and recent developments. Future Med Chem 1: 1095-1111.
14. Zhang H, Chang M, Hansen CN, Basso DM, Noble-Haeusslein LJ, (2011) Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury Neurotherapeutics. 8: 206-220.
15. VanSaun MN, Matrisian LM, (2006) Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res C Embryo Today 78: 69-79.
16. Murphy G, Ward R, Hembry RM, Reynolds JJ, Kuhn K, et al. (1989) Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J 258: 463-472.
17. Woessner JF, (1991) Matrix metalloproteinases and their inhibitors in connective tissue remode-ling. Faseb J 5: 2145-2154.
18. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM, (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149.
19. Brinckerhoff CE, Rutter JL, Benbow U, (2000) Interstitial collagenases as marker of tumor progression. Clin Cancer Res 6: 4823-4830.
20. Van Themsche C, Potworowski EF, Pierre Y, (2004) Stromelysin-1 (MMP-3) is inducible in T lymphoma cells and accelerates the growth of lymphoid tumors in vivo. Biochem Biophys Res Commun 315: 884-891.
21. Westermarck J, Kahari VM, (1999) Regulation of matrix metalloproteinase expression in tumour invasion. FASE 13: 781-792.
22. Murphy G, Docherty AJ, (1992) The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7: 120-125.
23. Price SJ, Greaves DR, Watkins H, (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276: 7549-7558.
24. Ye S, (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19: 623-639.
25. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, et al. (1999) Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet 105: 418-423.
26. Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, et al. (2004) Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med 33: 405-409.
27. O-Charoenrat P, Khantapura P, (2006) The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 42: 257-267.
28. Zhou G, Zhai Y, Cui Y, Qiu W, Yang H, et al. (2007) Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma. Hum Mutat 28: 1091-1097.
29. Chaudhary AK, Singh M, Bharti AC, Singh M, Shukla S, et al. (2010) Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer 10: 369.
30. Vairaktaris E, Yapijakis C, Vasiliou S, Derka S, Nkenke E, et al. (2007) Association of-1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer. Anticancer Res 27: 4095-4100.
31. Hashimoto T, Uchida K, Okayama N, Imate Y, Suehiro Y, et al. (2004) Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett 211: 19-24.
32. Nishizawa R, Nagata M, Noman AA, Kitamura N, Fujita H, et al. (2007) The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer 7: 187.
33. Tu HF, Liu CJ, Chang CS, Lui MT, Kao SY, et al. (2006) The functional (-1171 5A->6A) polymorphisms of matrix metalloproteinase 3 gene as a risk factor for oral submucous fibrosis among male areca users. J Oral Pathol Med 35: 99-103.
34. Zinzindohoué F, Blons H, Hans S, Loriot MA, Houllier AM, et al. (2004) Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res 24: 2021-2026.
35. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, et al. (2008) A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 34: 450-455.
36. Nasr HB, Mestiri S, Chahed K, Bouaouina N, Gabbouj S, et al. (2007) Matrix metalloproteinase-1 (-1607) 1G/2G and-9 (-1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas. Clin Chim Acta 384: 57-63.
37. Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, et al. (2007) Functional-1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med 36: 409-414.
38. Higgins JPT, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. Br Med J 327: 557-560.
39. Yoshizaki T, Sato H, Furukawa M, Pagano JS, (1998) The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci 95: 3621-3626.